Entegrion to develop dehydrated blood products for U.S. Navy

08/7/2009 | American City Business Journals

The U.S. Navy has awarded two contracts worth $4 million to Entegrion for the development of blood-derived products. The first contract is for the development of Stasix, a powder containing dehydrated particles taken from human blood platelets that can be easily rehydrated and administered to halt a person's internal or external bleeding. The second is for the development of the firm's Resusix, a dehydrated human plasma product with decreased pathogens that is designed for infusion in patients to increase blood volume, treat blood clotting inconsistencies and stop bleeding.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ